GlaxoSmithKline (GSK) and the University of Pennsylvania School of Medicine announced today that GSK has provided Penn with an unrestricted grant of $10 million to support academic research.

"We at GSK are fortunate that the Delaware Valley, home to so many of our Research and Development staff, is also home to such a leading academic research center as the University of Pennsylvania," said Tachi Yamada, Chairman, Research and Development, GSK. "We are hopeful that this grant will further the important research being done at Penn and facilitate scientific interchange between its scientists and our own. GSK and Penn are working towards a shared goal -- increasing our understanding of human disease and finding new treatments for the patients who need them."

"We are delighted to receive this grant and look forward to exploring mutual scientific interests of Penn and GSK," said Dr. Arthur H. Rubenstein, Executive Vice President of the University of Pennsylvania for the Health System and Dean of the School of Medicine. "This generous grant will permit our researchers to continue to aggressively pursue the translational nature of our work -- which seeks to transform knowledge gained at the benchside into safe and effective therapies and treatments that improve patient care."